Skip to main content
. 2020 Oct 12;25(12):1075–1083. doi: 10.1002/onco.13540

Figure 2.

Figure 2

Kaplan‐Meier analysis of thrombosis‐free survival. A Kaplan‐Meier analysis with log‐rank test was used to compare the thrombosis‐free survival between twice‐daily apixaban 2.5 mg versus placebo for (A) all patients enrolled into the AVERT study for whom baseline D‐dimer values were available and (B) individuals in the AVERT study with a 6‐month predicted risk of venous thromboembolism ≥8% or (C) 6‐month predicted risk of <8%. (A): Thromboprophylaxis with apixaban led to an improved thrombosis‐free survival compared with placebo with an absolute risk reduction (ARR) of 5.9% at 180 days (number needed to treat [NNT] = 17; p < .05). (B): Among patients with a 6‐month predicted risk ≥8%, apixaban had a 180‐day ARR of 17.9% (NNT = 6; p < .01). (C): Individuals with a 6‐month predicted risk <8% derived no benefit in thrombosis‐free survival when receiving prophylaxis with apixaban compared with placebo (p = .84). Abbreviation: CI, confidence interval.